Company intelligence / Profile preview

Nuvono

New York, New York, United Statesnuvono.com ↗

Ownership: Private
Development stage: Other

Overview

Taletrectinib has completed pivotal studies showing high response rates in ROS1-positive NSCLC. NDA submitted to FDA with Priority Review; potential U.S. commercial launch expected after June 23 PDUFA date. Expanded Access Program available for taletrectinib in the U.S. Other programs are advancing through early clinical or preclinical stages.

Therapeutic areas: Oncology
Modalities: Small moleculeDrug-drug conjugateMonoclonal antibody (preclinical pipeline)
Industry: Biotech

Partnerships

None specifically listed as major pharma partnerships; collaborations likely via acquired AnHeart Therapeutics and CROs for trials.

Beyond the preview

Go deeper on Nuvono.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuvono.

Explore the full profile